Immuneering Corporation (NASDAQ:IMRX) is among the best fast money stocks to buy now. Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company’s positive clinical trial outcome for its lead drug candidate. On Wednesday, Immuneering Corporation (NASDAQ:IMRX) reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together ...